Latest Commercialisation News

Volt Resources has reached a key technical milestone by consistently producing ultra-high purity graphite using a proprietary, hydrofluoric acid-free process, paving the way for U.S.-based battery-grade graphite production.

Hazer Group has made significant strides in commercialising its methane pyrolysis technology, advancing key partnerships and strengthening its intellectual property portfolio amid a tightening global graphite market.

4DMedical secures a major commercial breakthrough with Stanford University adopting its FDA-cleared CT, VQ™ technology, while its partnership with AstraZeneca rapidly scales lung screening across Brazil.

Vitrafy Life Sciences has delivered its first production unit of the next-generation cryopreservation device, advanced its US commercial footprint, and maintained a strong financial position heading into FY2026.

Weebit Nano has reported a record quarter with A$7.3 million in customer receipts, securing three key product agreements and progressing critical technology milestones at leading semiconductor fabs.

Bass Oil Limited reported a 3% rise in September oil production, driven by a 20% uplift in Indonesian output, while awaiting regulatory approval for a strategic gas field acquisition.

Invion Limited has partnered with Protect Animal Health to explore Photosoft™, a novel photodynamic therapy, as a treatment for cancer in companion animals, targeting a booming pet cancer market.

Tasman Resources has raised $2 million through a two-tranche placement to fund a promising drilling campaign at Parkinson Dam and broaden its project portfolio, alongside appointing a new director to steer its strategic ambitions.

Iondrive Limited has inked a binding term sheet with LAT66 Limited to apply its innovative Deep Eutectic Solvent technology to cobalt-rich concentrates from Finland’s Kuusamo projects, marking a strategic step beyond battery recycling into primary mineral processing.

Neurizon Therapeutics has been granted a key Australian patent for its lead drug candidate NUZ-001, extending protection for treatments targeting ALS, Alzheimer's, and other neurodegenerative diseases through 2041. This milestone complements earlier US patent grants and sets the stage for upcoming clinical trials.

Nexsen Limited has initiated clinical trials for its StrepSure® GBS Rapid Sensor, a next-generation diagnostic device aimed at improving maternal health outcomes. The trial's success could pave the way for regulatory approval and early market penetration by the second half of 2026.

Genetic Signatures Ltd reports a robust start to FY2026 with a 20% quarterly sales increase, driven by new US contracts and strong growth in EMEA and Australia. The company also bolsters its leadership with a new CTO appointment.